Algert Global LLC Makes New $637,000 Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Algert Global LLC acquired a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 5,964 shares of the specialty pharmaceutical company's stock, valued at approximately $637,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in JAZZ. Vanguard Group Inc. raised its position in Jazz Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company's stock valued at $776,551,000 after purchasing an additional 84,941 shares in the last quarter. LSV Asset Management raised its holdings in shares of Jazz Pharmaceuticals by 4.2% during the 2nd quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company's stock valued at $264,750,000 after buying an additional 99,705 shares in the last quarter. Pacer Advisors Inc. lifted its position in Jazz Pharmaceuticals by 40.7% in the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company's stock worth $194,346,000 after buying an additional 527,187 shares during the last quarter. Capital World Investors purchased a new stake in Jazz Pharmaceuticals in the first quarter worth approximately $171,943,000. Finally, Baupost Group LLC MA grew its position in Jazz Pharmaceuticals by 52.8% during the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company's stock valued at $136,000,000 after acquiring an additional 440,552 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on JAZZ. Royal Bank of Canada boosted their price objective on shares of Jazz Pharmaceuticals from $174.00 to $175.00 and gave the stock an "outperform" rating in a report on Friday. Cantor Fitzgerald reissued an "overweight" rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Robert W. Baird reduced their price objective on Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating on the stock in a research note on Thursday, August 1st. HC Wainwright reissued a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Finally, Needham & Company LLC restated a "buy" rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $173.14.

Jazz Pharmaceuticals Trading Up 0.8 %

NASDAQ:JAZZ traded up $0.82 during trading hours on Friday, hitting $109.38. The company had a trading volume of 330,587 shares, compared to its average volume of 686,129. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. The stock has a 50-day moving average price of $111.02 and a 200 day moving average price of $110.29. The company has a market capitalization of $6.90 billion, a PE ratio of 22.55, a price-to-earnings-growth ratio of 1.36 and a beta of 0.57. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $137.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. On average, equities research analysts predict that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Insider Activity

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company's stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares of the company's stock, valued at $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.